{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-007968","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.588003+00:00","generated_at":"2026-05-15T14:28:01.241640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxart reports FY2025 net income of $16.3M vs loss; revenue $237.3M; cash runway into Q2 2027","bullets":["Net income $16.3M ($0.07 EPS) vs net loss $66.9M ($0.33 loss) in FY2024.","Revenue $237.3M, up from $28.7M, driven by BARDA contract and Dynavax collaboration.","Cash, equivalents & investments $63.8M; runway into Q2 2027.","COVID-19 Phase 2b sentinel cohort data (400 subjects) expected early Q2 2026; main cohort topline Q4 2026.","Published Phase 1 norovirus data shows passive antibody transfer to infants via breast milk; next trial dependent on partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-007968","json":"https://secwatch.observer/filing/0001437749-26-007968.json","markdown":"https://secwatch.observer/filing/0001437749-26-007968.md","text":"https://secwatch.observer/filing/0001437749-26-007968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/0001437749-26-007968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/vxrt20260311_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:28:01.241640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}